Phase 2 Study of AKCEA-ANGPTL3-LRx (ISIS 703802) in Participants With Familial Chylomicronemia Syndrome (FCS)
Status:
Completed
Trial end date:
2018-09-04
Target enrollment:
Participant gender:
Summary
This is a single center, open-label study to evaluate the efficacy of AKCEA-ANGPTL3-LRx for
reduction of triglyceride (TG) levels in participants with FCS.